Immunic Inc (IMUX) concluded trading on Wednesday at a closing price of $0.99, with 8.83 million shares of worth about $8.74 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.77% during that period and on April 30, 2025 the price saw a loss of about -22.65%. Currently the company’s common shares owned by public are about 95.82M shares, out of which, 92.92M shares are available for trading.
Stock saw a price change of -9.99% in past 5 days and over the past one month there was a price change of -9.17%. Year-to-date (YTD), IMUX shares are showing a performance of -0.99% which decreased to -18.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.83 but also hit the highest price of $2.11 during that period. The average intraday trading volume for Immunic Inc shares is 720.33K. The stock is currently trading -2.26% below its 20-day simple moving average (SMA20), while that difference is down -9.90% for SMA50 and it goes to -19.81% lower than SMA200.
Immunic Inc (NASDAQ: IMUX) currently have 95.82M outstanding shares and institutions hold larger chunk of about 51.75% of that.
The stock has a current market capitalization of $94.87M and its 3Y-monthly beta is at 1.69. It has posted earnings per share of -$1.03 in the same period. It has Quick Ratio of 1.77 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMUX, volatility over the week remained 15.01% while standing at 11.09% over the month.
Stock’s fiscal year EPS is expected to rise by 21.00% while it is estimated to increase by 8.10% in next year.
Coverage by H.C. Wainwright stated Immunic Inc (IMUX) stock as a Buy in their note to investors on November 25, 2024, suggesting a price target of $10 for the stock. On September 09, 2024, Leerink Partners Resumed their recommendations, while on August 27, 2024, B. Riley Securities Initiated their ratings for the stock with a price target of $6. Stock get a Mkt perform rating from SVB Leerink on October 21, 2022.
